{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:57:21Z","timestamp":1784098641867,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the absence of Phase III clinical trial data to support their use, 3.4% of all neurotoxin treatments performed internationally for esthetic purposes in 2020 were performed in patients 65\u2009years of age and older.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the efficacy and safety of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in the subset of Phase III clinical trial participants who were 65\u2009years of age and older.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Post hoc analyses were performed on all patients who had been treated with a single dose of 20\u2009U prabotulinumtoxinA in the three 150\u2010day, placebo\u2010controlled Phase III glabellar line clinical studies. Patients were grouped by age: \u226565\u2009years (<jats:italic>n<\/jats:italic>\u2009=\u200970) versus &lt;65\u2009years (<jats:italic>n<\/jats:italic>\u2009=\u2009667). The endpoints of primary interest were the proportion of responders with a \u22651\u2010point improvement from baseline at maximum frown on the 4\u2010point Glabellar Line Scale and treatment\u2010related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For the efficacy endpoint of primary interest, responder rates among patients 65\u2009years of age and older were numerically less than those of patients less than 65\u2009years by an absolute mean difference of just \u22122.7% across all visits; none of the differences at any visit were statistically significant. The most common treatment\u2010related adverse event was headache, occurring in 5.7% of those 65\u2009years of age and older and in 9.7% of those less than 65\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>20\u2009U prabotulinumtoxinA administered for the treatment of glabellar lines was efficacious in patients 65\u2009years of age and older; it was also well tolerated by this cohort.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.15783","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:15:26Z","timestamp":1682604926000},"page":"1745-1756","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65\u2009years of age and older: The fourth in a series of post hoc analyses of the phase <scp>III<\/scp> clinical study data"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-5681","authenticated-orcid":false,"given":"Sue Ellen","family":"Cox","sequence":"first","affiliation":[{"name":"Aesthetic Solutions  Chapel Hill North Carolina USA"},{"name":"Department of Dermatology University of North Carolina at Chapel Hill School of Medicine  Chapel Hill North Carolina USA"},{"name":"Department of Dermatology Duke University Medical Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ascher","sequence":"additional","affiliation":[{"name":"Paris Academy  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui L.","family":"Avelar","sequence":"additional","affiliation":[{"name":"Evolus, Inc.  Newport Beach California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Beer","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Research Institute of the Southeast  West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Cartier","sequence":"additional","affiliation":[{"name":"Private Practice, Centre M\u00e9dical Saint\u2010Jean  Arras France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fagien","sequence":"additional","affiliation":[{"name":"Private Practice, Cosmetic Oculoplastic Surgery  Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Solish","sequence":"additional","affiliation":[{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"The International Society of Aesthetic Plastic Surgery.ISAPS International Survey on Aesthetic\/Cosmetic Procedures.2020. Accessed July 6 2022.https:\/\/www.isaps.org\/wp\u2010content\/uploads\/2022\/01\/ISAPS\u2010Global\u2010Survey_2020.pdf"},{"key":"e_1_2_12_3_1","unstructured":"The Aesthetic Society.Aesthetic Plastic Surgery National Databank Statistics.2019. Accessed July 28 2022.https:\/\/cdn.theaestheticsociety.org\/media\/statistics\/2019\u2010TheAestheticSocietyStatistics.pdf"},{"key":"e_1_2_12_4_1","unstructured":"Revance Therapeutics Inc.Highlights of Prescribing Information. Daxxify (daxibotulinumtoxinA\u2010Lanm) for Injection for Intramuscular Use.2022. Accessed September 23 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761127s000lbl.pdf"},{"key":"e_1_2_12_5_1","unstructured":"Allergan Inc.Highlights of Prescribing Information. Botox Cosmetic (OnabotulinumtoxinA) for Injection for Intramuscular Use.2020. Accessed July 6 2022.https:\/\/www.rxabbvie.com\/pdf\/botox\u2010cosmetic_pi.pdf"},{"key":"e_1_2_12_6_1","unstructured":"Merz Pharmaceuticals LLC.Highlights of Prescribing Information. Xeomin (incobotulinumtoxinA) for Injection for Intramuscular or Intraglandular Use.2021. Accessed July 6 2022.https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=ccdc3aae\u20106e2d\u20104cd0\u2010a51c\u20108375bfee9458&type=display"},{"key":"e_1_2_12_7_1","unstructured":"Ipsen Biopharm Ltd.Highlights of Prescribing Information. Dysport (AbobotulinumtoxinA) for Injection for Intramuscular Use.2020. Accessed July 6 2022.https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp\u2010content\/uploads\/2020\/07\/10002305\/DYS\u2010US\u2010004998_Dysport\u2010PI\u2010July\u20102020.pdf"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.121356"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PRS.0000076504.79727.62"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01235.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e3181b5641b"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.asj.2009.09.012"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000001903"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz110"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002864"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003456"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac210"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13702"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2010.08.029"},{"issue":"1","key":"e_1_2_12_20_1","first-page":"s5","article-title":"Re\u2010examining the optimal use of neuromodulators and the changing landscape: a consensus panel update","volume":"19","author":"Kaminer MS","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000475758.63709.23"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002119"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/ciia.2007.2.1.81"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:31:00Z","timestamp":1700677860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/jocd.15783"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15783","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"2023-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}